"As is the case with most countries in the Middle East, Israel rarely comes up in discussions of global 'safe havens', notes John Christy.

The editor of The Forbes International Investment Report explains, "But so far this year, Israel has been a pretty good place to hide from Wall Street's woes." Here he looks at one Israeli favorite, Cellcom Israel (NYSE: CEL).

"Putting stereotypes about risk aside, Israel offers a lot of interesting opportunities, even for fairly conservative investors. Cellcom Israel is a prime example. The company is Israel's largest mobile phone service provider, with sales of $1.6 billion in 2007.

"Since February 2007, the company has had a dual listing on both the New York and Tel Aviv stock exchanges. Discount Investment Corp. Ltd., one of Israel's largest business groups, owns just over 50% of the company.

"With 3.1 million subscribers, Cellcom has a 34% share of Israel's mobile telecom services market. Roughly three-quarters of Cellcom's subscribers are individuals, and the remaining 25% are corporate customers.

Continue reading Shalom: Forbes expert calls on Cellcom Israel (CEL)

Shalom: Forbes expert calls on Cellcom Israel (CEL) originally appeared on BloggingStocks on Thu, 19 Jun 2008 10:39:00 EST. Please see our terms for use of feeds.

"Analysts estimate the worldwide market for generics will increase from $75 billion to $125 billion by 2012," says Michael Shulman.

In his ChangeWave Biotech Investor he states, "The key question for us is: Who is going to make the most money from these expirations? And the 800-pound gorilla in this market is our long-time holding, Teva Pharmaceuticals (NASDAQ: TEVA).

"Teva is the largest and best generics company in the world with $9.4 billion in sales in 2007 and the gap between it and its competitors is growing. Teva has 331 products on the market, 65% more than its closest competitor.

"More importantly, based on its business model of a mix of proprietary and generic drugs, the company's operating margins are 10 points higher than competitors and that gap is widening. In fact, in the United States, the number of prescriptions filled with Teva generics is 50% more than its closest competitor.

"Be clear on this point: When it comes to generics, size does matter. The more a company sells, the more profit and cash it has available to do research and acquire more generics to add to its product list -- and the beat goes on.

Continue reading Teva: The 800-pound gorilla of generics

Teva: The 800-pound gorilla of generics originally appeared on BloggingStocks on Fri, 13 Jun 2008 14:00:00 EST. Please see our terms for use of feeds.